GPC3 and neoplasm: A single-arm, open-label, phase I clinical trial targeting GPC3 demonstrated that a patient with advanced HCC who received a single intratumoral injection of 7×19 CAR-T cells targeting GPC3 experienced tumor shrinkage within 10 days and achieved complete imaging remission by day 32, with no grade ≥3 adverse events reported (22).